Catalyst Funds Management Pty Ltd Acquires New Position in Sana Biotechnology, Inc. $SANA

Catalyst Funds Management Pty Ltd bought a new position in Sana Biotechnology, Inc. (NASDAQ:SANA) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 22,600 shares of the company’s stock, valued at approximately $62,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nisa Investment Advisors LLC grew its holdings in shares of Sana Biotechnology by 673.8% during the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after buying an additional 9,501 shares during the last quarter. Hoey Investments Inc. purchased a new stake in Sana Biotechnology during the 2nd quarter valued at $33,000. Good Life Advisors LLC bought a new stake in shares of Sana Biotechnology in the 2nd quarter worth $46,000. WealthPlan Investment Management LLC purchased a new position in shares of Sana Biotechnology in the second quarter worth $48,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Sana Biotechnology during the second quarter valued at $63,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Up 1.9%

SANA opened at $3.29 on Friday. The company’s 50 day moving average is $4.20 and its 200 day moving average is $3.49. The company has a market cap of $876.34 million, a price-to-earnings ratio of -3.39 and a beta of 1.94. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30.

Sana Biotechnology (NASDAQ:SANA) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.03. As a group, analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

SANA has been the topic of several recent analyst reports. Citizens Jmp increased their price objective on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Wedbush increased their price objective on shares of Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, JMP Securities set a $8.00 target price on shares of Sana Biotechnology in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.